302 related articles for article (PubMed ID: 28697650)
1. Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series.
Lalikian K; Parsiani R; Won R; Chang E; Turner RB
J Chemother; 2018 Apr; 30(2):124-128. PubMed ID: 28697650
[TBL] [Abstract][Full Text] [Related]
2. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients.
Lin JC; Aung G; Thomas A; Jahng M; Johns S; Fierer J
J Infect Chemother; 2013 Feb; 19(1):42-9. PubMed ID: 22797874
[TBL] [Abstract][Full Text] [Related]
3. Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience.
Johnson LB; Ramani A; Guervil DJ
BMC Infect Dis; 2019 Feb; 19(1):183. PubMed ID: 30791894
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ
Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.
Jacqueline C; Amador G; Caillon J; Le Mabecque V; Batard E; Miègeville AF; Biek D; Ge Y; Potel G; Hamel A
J Antimicrob Chemother; 2010 Aug; 65(8):1749-52. PubMed ID: 20530506
[TBL] [Abstract][Full Text] [Related]
6. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report.
Jongsma K; Joson J; Heidari A
J Antimicrob Chemother; 2013 Jun; 68(6):1444-5. PubMed ID: 23341127
[No Abstract] [Full Text] [Related]
8. In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.
Sanchez EH; Mendes RE; Sader HS; Allison GM
J Antimicrob Chemother; 2016 Jun; 71(6):1736-8. PubMed ID: 26861570
[No Abstract] [Full Text] [Related]
9. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA.
Stryjewski ME; Jones RN; Corey GR
Diagn Microbiol Infect Dis; 2015 Mar; 81(3):183-8. PubMed ID: 25583130
[TBL] [Abstract][Full Text] [Related]
10. Characterization of an osteomyelitis case caused by dalbavancin, ceftaroline, and vancomycin non-susceptible methicillin-resistant Staphylococcus aureus.
Dahdouh E; Díaz-Pollán B; Falces-Romero I; Mingorance J; Gómez-Gil R
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):2029-2032. PubMed ID: 33686556
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and therapeutic outcomes of hematogenous vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus.
Park KH; Chong YP; Kim SH; Lee SO; Choi SH; Lee MS; Jeong JY; Woo JH; Kim YS
J Infect; 2013 Dec; 67(6):556-64. PubMed ID: 23916563
[TBL] [Abstract][Full Text] [Related]
12. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
[TBL] [Abstract][Full Text] [Related]
13. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
14. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.
Ho TT; Cadena J; Childs LM; Gonzalez-Velez M; Lewis JS
J Antimicrob Chemother; 2012 May; 67(5):1267-70. PubMed ID: 22311935
[TBL] [Abstract][Full Text] [Related]
15. Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Zasowski EJ; Trinh TD; Claeys KC; Casapao AM; Sabagha N; Lagnf AM; Klinker KP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895012
[TBL] [Abstract][Full Text] [Related]
16. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.
Polenakovik HM; Pleiman CM
Int J Antimicrob Agents; 2013 Nov; 42(5):450-5. PubMed ID: 23993067
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy With Vancomycin and Ceftaroline for Refractory Methicillin-resistant Staphylococcus aureus Bacteremia: A Case Series.
Gritsenko D; Fedorenko M; Ruhe JJ; Altshuler J
Clin Ther; 2017 Jan; 39(1):212-218. PubMed ID: 28038791
[TBL] [Abstract][Full Text] [Related]
18. PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.
Long SW; Olsen RJ; Mehta SC; Palzkill T; Cernoch PL; Perez KK; Musick WL; Rosato AE; Musser JM
Antimicrob Agents Chemother; 2014 Nov; 58(11):6668-74. PubMed ID: 25155594
[TBL] [Abstract][Full Text] [Related]
19.
Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
[TBL] [Abstract][Full Text] [Related]
20. High-level ceftaroline resistance in a paediatric patient with invasive methicillin-resistant Staphylococcus aureus infection without previous ceftaroline exposure.
Ferguson CL; Cowart MC; Jordan-Villegas A; Laham F
J Clin Pharm Ther; 2021 Apr; 46(2):524-527. PubMed ID: 33236793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
